Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377929 | 0.91 | ALDH1A1 (0.44) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL18025238 | 0.89 | CTSD (0.35) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL22052472 | 0.78 | KDM4E (0.35) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL2236854 | 0.75 | ALDH1A1 (0.65) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL9007188 | 0.73 | CTSD (0.41) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL27633670 | 0.73 | ALDH1A1 (0.62) | KDM4ECTSDKDM5CPHF8KDM2A | |
| Water SCHEMBL28826322 | 0.73 | ALDH1A1 (0.62) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL23265399 | 0.72 | — | — | |
| SCHEMBL18025485 | 0.72 | CTSD (0.39) | KDM4ECTSDALDH1A1LMNAKDM5A | |
| Water SCHEMBL28656859 | 0.72 | ALDH1A1 (0.60) | KDM4ECTSDKDM5CPHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3420047-B1 | HYDRAZIDE CROSSLINKED POLYMER EMULSIONS FOR USE IN CRUDE OIL RECOVERY | ECOLAB USA INC (US) | 2023-01-11 | — | — | EP | claimed |
| US-20220347655-A1 | WATER-ABSORBENT CROSS-LINKED POLYMERIC POLYCARBOXYLIC ACID AND METHODS OF MAKING | ECOVIA RENEWABLES INC. (US) | 2022-11-03 | — | — | US | claimed |
| US-20220304304-A1 | Compositions of Dicarboxylic Acid Derivatives | UPL LTD (IN) | 2022-09-29 | — | — | US | claimed |
| CN-114984875-A | Metal-hydrazide coordination self-assembly nanosphere and preparation method and application thereof | 西安交通大学 | 2022-09-02 | — | — | CN | claimed |
| EP-4038140-A1 | WATER-ABSORBENT CROSS-LINKED POLYMERIC POLYCARBOXYLIC ACID AND METHODS OF MAKING | Ecovia Renewables Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114502643-A | Water-absorbing cross-linked polymeric polycarboxylic acids and process for preparing same | 埃科维亚可再生能源有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114071998-A | Composition of dicarboxylic acid derivatives | UPL有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-112472672-B | Polypeptide-polysaccharide graft copolymer based platinum nano prodrug and preparation method and application thereof | 西安交通大学 | 2022-01-25 | — | — | CN | claimed |
| CN-112608397-B | Platinum antitumor drug-polysaccharide polymer nano prodrug and preparation method and application thereof | 西安交通大学 | 2021-12-28 | — | — | CN | claimed |
| CN-112426981-B | Metal ion crosslinked hydrogel and preparation method and application thereof | 西安交通大学 | 2021-12-28 | — | — | CN | claimed |
| US-20030125471-A1 | Curable resin composition | KANSAI PAINT CO., LTD. (JP) | 2003-07-03 | — | — | US | claimed |
| US-6559231-B2 | Copolymer of an unsaturated monomer having a maleimide group; compound having at least 2 hydrazide, semicarbazide or hydrazone groups | KANSAI PAINT CO., LTD. (JP) | 2003-05-06 | — | — | US | claimed |
| EP-1300429-A1 | Curable resin composition | KANSAI PAINT CO., LTD. (JP) | 2003-04-09 | — | — | EP | claimed |
| US-20030065068-A1 | Copolymer of ethylenically unsaturated maleimide group and carbonyl group monomers and a compound having hydrazide, semicarbazide or hydrazone groups | KANSAI PAINT CO., LTD. (JP) | 2003-04-03 | — | — | US | claimed |
| EP-1298152-A1 | Curable resin composition | KANSAI PAINT CO., LTD. (JP) | 2003-04-02 | — | — | EP | claimed |
| US-6538062-B2 | Emulsion polymer of ethylenic unsaturated monomer having glass transition temperature of from -50 to 150 degrees C, compound having at least two hydrazide groups in its molecule | DAI NIPPON TORYO CO., LTD. (JP) | 2003-03-25 | — | — | US | claimed |
| EP-1262495-A1 | Curable resin composition | KANSAI PAINT CO., LTD. (JP) | 2002-12-04 | — | — | EP | claimed |
| US-20020128379-A1 | Curing type water base resin composition | KANSAI PAINT CO., LTD. (JP) | 2002-09-12 | — | — | US | claimed |
| US-20020103278-A1 | Waterborne coating composition | SHERWIN-WILLIAMS COMPANY, THE | 2002-08-01 | — | — | US | claimed |
| EP-1211293-A2 | Curing type water base resin composition | KANSAI PAINT CO., LTD. (JP) | 2002-06-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304304-A1 | Compositions of Dicarboxylic Acid Derivatives | MDH2, MDH1, DLST | KDM4E 765/4885CTSD 3758/4885KDM5C 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.